Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

30.52 +0.57 (+1.90%)

Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? ↗

Today 8:50 EDT

Pfizer's post-COVID comeback is still only in the early stages.

Via The Motley Fool

Topics Intellectual Property

S&P 500 Most-Active Stocks: Oct. 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call ↗

October 30, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company...

Via MarketBeat

Topics ETFs Earnings

1 stock under $50 worth investigating and 2 we ignore

October 29, 2026

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

Via StockStory

Topics Energy

1 cash-producing stock with competitive advantages and 2 we brush off

October 28, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

October 27, 2026

The stocks listed here yield up to 5.8%.

Via The Motley Fool

Topics Bonds

3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist ↗

October 27, 2026

These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.

Via The Motley Fool

Topics ETFs Intellectual Property

Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma

October 27, 2026

From Pfizer Inc.

Via Business Wire

Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting

October 26, 2026

From Pfizer Inc.

Via Business Wire

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market

October 26, 2026

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:MRNA),(NASDAQ:IOVA),(NASDAQ:GMAB),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

October 24, 2026

From Pfizer Inc.

Via Business Wire

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem ↗

October 24, 2026

Pfizer has a plan to bounce back from recent obstacles.

Via The Motley Fool

Topics Intellectual Property Stocks

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗

October 23, 2026

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

Via MarketBeat

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? ↗

October 23, 2026

One of these pharma stocks offers more income, but the other offers a safer dividend.

Via The Motley Fool

Topics Intellectual Property

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗

October 23, 2026

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Via The Motley Fool

Topics ETFs

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option ↗

October 22, 2026

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader...

Via MarketBeat

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer ↗

October 22, 2026

They definitely matter... up to a point.

Via The Motley Fool

Topics Bonds Economy

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue ↗

October 22, 2026

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Via The Motley Fool

Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs ↗

October 21, 2026

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

Via MarketBeat

Topics Artificial Intelligence ETFs

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗

October 21, 2026

This company made headlines with its coronavirus vaccine.

Via The Motley Fool

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack

October 20, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Most Active S&P 500 Stocks in Today's Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? ↗

October 19, 2026

The stock has outperformed the market this year, and it still looks heavily undervalued.

Via The Motley Fool

Topics Artificial Intelligence

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗

October 18, 2026

It has been a volatile year for the biotech.

Via The Motley Fool

Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway. ↗

October 18, 2026

Not every company is at risk.

Via The Motley Fool

Topics Economy Intellectual Property

Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year ↗

October 18, 2026

These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.

Via The Motley Fool

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗

October 17, 2026

The gene-editing biotech stock is down more than 12% this year.

Via The Motley Fool

Topics ETFs Lawsuit

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗

October 17, 2026

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Via The Motley Fool

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends ↗

October 16, 2026

You'd need to invest over $200,000 in the pharma leader at its current price.

Via The Motley Fool

Topics Intellectual Property

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? ↗

October 16, 2026

Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Pfizer (NY:PFE)

All News about Pfizer

Popular Pages